



100-0218 - STEMdiff[™] Atrial Cardiomyocyte Differentiation Supplement C (10X)

Revision Date 27-Jul-2021 Revision Number 2

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier **Product Name** STEMdiff[™] Atrial Cardiomyocyte Differentiation Supplement C (10X) Other means of identification 100-0218 **Catalog Number Document Number** 1000009411 Synonyms None Recommended use of the chemical and restrictions on use **Recommended Use** Laboratory reagent Details of the supplier of the safety data sheet Manufacturer/Supplier STEMCELL Technologies Canada Inc. Suite 500 - 1618 Station Street Vancouver, British Columbia V6A 1B6 Canada Emergency telephone number 1-800-667-0322 **Emergency Telephone** 2. HAZARDS IDENTIFICATION Classification This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) Hazards not otherwise classified (HNOC) Not applicable Label elements

Hazard statements

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)





100-0218 - STEMdiff[™] Atrial Cardiomyocyte Differentiation Supplement C (10X)

Appearance opaque

Physical state Liquid

The product contains no substances which at their given concentration, are considered to be hazardous to health.

Odor No data available

Revision Date 27-Jul-2021 Revision Number 2

Other Information

Not applicable

Unknown acute toxicity 0 % of the mixture consists of ingredient(s) of unknown toxicity

0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity

0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance

Not applicable.

Mixture

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)

*The exact percentage (concentration) of composition has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of first aid measures

Inhalation	Remove to fresh air.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Wash skin with soap and water.





100-0218 - STEMdiff[™] Atrial Cardiomyocyte Differentiation Supplement C (10X)

Revision Date 27-Jul-2021 **Revision Number** 2

Ingestion	Clean mouth with water and drink afterwards plenty of water.	
Most important symptoms and effe	cts, both acute and delayed	
Symptoms	No information available.	
Indication of any immediate medica	I attention and special treatment needed	
Note to physicians	Treat symptomatically.	
	5. FIRE-FIGHTING MEASURES	
Suitable Extinguishing Media	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.	
Unsuitable extinguishing media	CAUTION: Use of water spray when fighting fire may be inefficient.	
Specific hazards arising from the chemical	No information available.	
Explosion data Sensitivity to Mechanical Impact None. Sensitivity to Static Discharge None.		
Special protective equipment for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.	
6. ACCIDENTAL RELEASE MEASURES		
Personal precautions, protective equipment and emergency procedures		
Personal precautions	Ensure adequate ventilation.	

Environmental precautions

See Section 12 for additional Ecological Information. **Environmental precautions**

Methods and material for containment and cleaning up

Methods for containment

Prevent further leakage or spillage if safe to do so.





100-0218 - STEMdiff[™] Atrial Cardiomyocyte Differentiation Supplement C (10X)

Revision Date 27-Jul-2021 Revision Number 2

Methods for cleaning up	Pick up and transfer to properly labeled containers.
Prevention of secondary hazards	Clean contaminated objects and areas thoroughly observing environmental regulations.

7. HANDLING AND STORAGE

riecaulous for sale nanding	
Advice on safe handling	Handle in accordance with good industrial hygiene and safety practice.
Conditions for safe storage, including any incompatibilities	
Storage Conditions	Store in accordance with information listed on the Product Information Sheet (PIS).

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Precautions for safe handling

Exposure LimitsThis product, as supplied, does not contain any hazardous materials with occupational
exposure limits established by the region specific regulatory bodies.

Appropriate engineering controls

Engineering controls	Showers
	Eyewash stations
	Ventilation systems.

Eye/face protection No special protective equipment required.

Individual protection measures, such as personal protective equipment

Skin and body protection No special protective equipment required.

- **Respiratory protection** No protective equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and evacuation may be required.
- Other protectionThis product contains material derived from human plasma. Donors have been tested and
found negative for HIV-1 and -2, hepatitis B, and hepatitis C prior to donation. However, this
product should be considered potentially infectious. Use controls and personal protection





100-0218 - STEMdiff[™] Atrial Cardiomyocyte Differentiation Supplement C (10X)

Revision Date 27-Jul-2021 **Revision Number** 2

appropriate for biohazardous infectious materials, as described in: Canadian Biosafety Standards and Guidelines (CBSG), Second Edition.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state	Liquid
Appearance	opaque
Color	light yellow
Odor	No data available
Odor threshold	No data available
Property_	Values
pH	No data available
Melting point / freezing point	No data available
Boiling point / boiling range	No data available
Flash point	No data available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility in other solvents	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Explosive properties	No data available
Oxidizing properties	No information available
Other Information	
Other Information Softening point	No information available
Molecular weight	No information available
Molecular formula	No information available
VOC Content (%)	No information available
Liquid Density	No information available
Bulk density	No information available
Buik defibily	

Remarks • Method

None known None known None known None known None known None known None known

None known None known None known None known None known None known None known None known None known None known





100-0218 - STEMdiff[™] Atrial Cardiomyocyte Differentiation Supplement C (10X)

Revision Date 27-Jul-2021 **Revision Number** 2

10. STABILITY	AND REACTIVITY

Reactivity	No information available.
Chemical stability	Stable under normal conditions.
Possibility of hazardous reactions	None under normal processing.
Conditions to avoid	None known based on information supplied.
Incompatible materials	None known based on information supplied.
Hazardous decomposition products None known based on information supplied.	

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Product Information	
Inhalation	Specific test data for the substance or mixture is not available.
Eye contact	Specific test data for the substance or mixture is not available.
Skin contact	Specific test data for the substance or mixture is not available.
Ingestion	Specific test data for the substance or mixture is not available.
Symptoms related to the physical, chemical and toxicological characteristics	
Symptoms	No information available.

Numerical measures of toxicity

Acute toxicity

Unknown acute toxicity

- 0 % of the mixture consists of ingredient(s) of unknown toxicity 0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity
- 0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)





100-0218 - STEMdiff[™] Atrial Cardiomyocyte Differentiation Supplement C (10X)

Revision Date 27-Jul-2021 Revision Number 2

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation	No information available.
Product Information	
Serious eye damage/eye irritation	No information available.
Product Information	
Respiratory or skin sensitization	No information available.
Product Information	
Germ cell mutagenicity	No information available.
Product Information	
Carcinogenicity	No information available.
Reproductive toxicity	No information available.
	Product Information
STOT - single exposure	No information available.
	Product Information
STOT - repeated exposure	No information available.
	Product Information
Aspiration hazard	No information available.

12. ECOLOGICAL INFORMATION

Ecotoxicity Product Information	
Persistence and degradability	No information available.
Bioaccumulation	There is no data for this product.
Other adverse effects	No information available.

13. DISPOSAL CONSIDERATIONS

Waste treatment methods



Supplement C (10X)



SAFETY DATA SHEET

100-0218 - STEMdiff[™] Atrial Cardiomyocyte Differentiation Rev

Revision Date 27-Jul-2021 Revision Number 2

Waste from residues/unused products	Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.
Contaminated packaging	Do not reuse empty containers.

14. TRANSPORT INFORMATION

DOT	Not regulated
TDG	Not regulated
<u>MEX</u>	Not regulated
ICAO (air)	Not regulated
IATA	Not regulated
IMDG	Not regulated
RID	Not regulated
ADR	Not regulated
ADN	Not regulated

15. REGULATORY INFORMATION

International Inventories	
TSCA	Does not comply
DSL/NDSL	Does not comply
EINECS/ELINCS	Complies
ENCS	Does not comply
IECSC	Does not comply
KECL	Does not comply
PICCS	Does not comply
AICS	Does not comply

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances





100-0218 - STEMdiff[™] Atrial Cardiomyocyte Differentiation Supplement C (10X)

Revision Date 27-Jul-2021 Revision Number 2

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

US Federal Regulations

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazard Categories

Acute health hazard	No
Chronic Health Hazard	No
Fire hazard	No
Sudden release of pressure hazard	No
Reactive Hazard	No

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

US State Regulations

California Proposition 65

This product contains the following Proposition 65 chemicals.

Chemical name	California Proposition 65	
Trade secret -	Carcinogen	
	Developmental	

U.S. State Right-to-Know Regulations

US State Regulations

Chemical name	New Jersey	Massachusetts	Pennsylvania
Water	-	-	Х





100-0218 - STEMdiff[™] Atrial Cardiomyocyte Differentiation Supplement C (10X)

Revision Date 27-Jul-2021 Revision Number 2

7732-18-5			
Trade secret	Х	Х	Х
Sodium Phosphate Dibasic 7558-79-4	Х	Х	Х

U.S. EPA Label Information

EPA Pesticide Registration Number Not applicable

16. OTHER INFORMATION, INCLUDING DATE OF PREPARATION OF THE LAST REVISION

Prepared By,

Quality Control. STEMCELL Technologies Canada Inc.

Revision Date 27-Jul-2021

Revision Note No information available.

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.

End of Safety Data Sheet